Can You Mix Stelara and Humira?
No, you should not mix Stelara (ustekinumab) and Humira (adalimumab). Both are biologics used for conditions like psoriasis, Crohn's disease, and ulcerative colitis, but combining them increases risks without proven benefits. Stelara targets IL-12/IL-23 cytokines, while Humira blocks TNF-alpha, and their mechanisms can overlap in ways that heighten immunosuppression.[1]
What Happens If You Combine Them?
Mixing leads to higher infection risk, including serious ones like tuberculosis reactivation or sepsis, due to compounded immune suppression. Studies and case reports show elevated adverse events, such as severe infections or infusion reactions, when TNF inhibitors like Humira are paired with IL inhibitors like Stelara. No clinical guidelines endorse this combo; it's off-label and untested in large trials.[2][3]
Why Do Doctors Avoid Prescribing Both?
Guidelines from the American College of Rheumatology and AGA recommend monotherapy or approved switches, not combos, for inflammatory bowel disease or psoriasis. Dual biologics are rare, reserved for refractory cases under specialist monitoring, often with different classes (e.g., anti-TNF + integrin inhibitor). Stelara-Humira lacks supporting data and raises malignancy concerns long-term.[4]
Safer Alternatives to Switching or Combining
- Switch directly: From Humira to Stelara if one fails—Stelara shows better durability in head-to-head trials for Crohn's.[5]
- Other biologics: Skyrizi (risankizumab) or Tremfya (guselkumab) for IL-23 specificity; Entyvio (vedolizumab) for gut-selective action.
- Small molecules: Add JAK inhibitors like Xeljanz if biologics fail, but still avoid untested mixes.
Discuss with a gastroenterologist or rheumatologist; they may test for antibodies to guide changes.
What Patients Report and Real-World Risks
Patient forums note worsened flares or infections when self-mixing, though anecdotal. FDA labels warn against concurrent immunosuppressants. Monitor via bloodwork for neutropenia or hepatotoxicity if trialed experimentally.[6]
[1] FDA Stelara Prescribing Information: https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/761044s026lbl.pdf
[2] FDA Humira Prescribing Information: https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/125057s412lbl.pdf
[3] Clinical Pharmacology Review (JAMA Dermatol, 2020): https://jamanetwork.com/journals/jamadermatology/fullarticle/2767884
[4] AGA Guidelines (Gastroenterology, 2021): https://www.gastrojournal.org/article/S0016-5085(21)00674-3/fulltext
[5] UNIFI Trial (NEJM, 2019): https://www.nejm.org/doi/full/10.1056/NEJMoa1900750
[6] Drugs.com Interactions Checker: https://www.drugs.com/drug-interactions/adalimumab-with-ustekinumab-143-0-3438-0.html